Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Disease Patients Clear all
Terminated Phase 1 Interventional

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

NCT05956509
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
ABBV-950, BOTOX, Placebo for ABBV-950
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Carlsbad, California • Downey, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 8, 2026, 2:18 AM EDT
Recruiting Not applicable Interventional

Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

NCT07029243
View directory record Official record
Conditions
Cirrhosis, Frailty, Sarcopenia
Interventions
HEAL-ME digital app, Creatine supplementation, Whey protein supplementation, Placebo
Behavioral · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

NCT01855360
View directory record Official record
Conditions
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions
Tauroursodeoxycholic Acid and Doxycycline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT03406780
View directory record Official record
Conditions
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
CAP-1002, Placebo
Biological · Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
10 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis

NCT00033891
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

Steroids Versus Gabapentin

NCT01495923
View directory record Official record
Conditions
Sciatica, Radiculopathy
Interventions
epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
17 Years to 100 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 8, 2026, 2:18 AM EDT
Terminated Early Phase 1 Interventional

Trial of Orencia in Patients With Myasthenia Gravis

NCT03059888
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Abatacept Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Early Phase 1 Interventional Results available

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586
View directory record Official record
Conditions
Neurofibromatosis, NF1, Neurofibromas
Interventions
Tasigna
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 8, 2026, 2:18 AM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 8, 2026, 2:18 AM EDT
Terminated Not applicable Interventional Results available

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279
View directory record Official record
Conditions
HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
Interventions
valsartan, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 8, 2026, 2:18 AM EDT
Recruiting Phase 2 Interventional

Descartes-08 in Autoantibody Myositis

NCT07391605
View directory record Official record
Conditions
Antisynthetase Syndrome
Interventions
Descartes-08, Placebo
Drug · Other
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

NCT03452488
View directory record Official record
Conditions
Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions
BIO101, Placebo
Drug
Lead sponsor
Biophytis
Industry
Eligibility
65 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
19
States / cities
Banning, California • Garden Grove, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 4 Interventional

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy

NCT00380913
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Cesamet™ (nabilone)
Drug
Lead sponsor
NEMA Research, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Aventura, Florida • Hollywood, Florida • Naples, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 8, 2026, 2:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

NCT05169060
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 1 Interventional

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

NCT00875446
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PLACEBO, GSK1223249
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 8, 2026, 2:18 AM EDT
Completed No phase listed Observational

Quantitative EEG During PSG in Patients With and Without Fibromyalgia

NCT01674179
View directory record Official record
Conditions
Fibromyalgia
Interventions
Not listed
Lead sponsor
SouthCoast Medical Group
Other
Eligibility
18 Years to 80 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer

NCT03139435
View directory record Official record
Conditions
Peripheral Neuropathy, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy, Questionnaire Administration, Ultrasound Tomography
Procedure · Other · Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

NCT01173055
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 8, 2026, 2:18 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Interventions
Bone Marrow Aspiration and Biopsy, Trametinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients

NCT03479008
View directory record Official record
Conditions
Critically Ill, Post Intensive Care Syndrome
Interventions
Therapeutic Vibration Device
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Pregabalin In Adolescent Patients With Fibromyalgia

NCT01020526
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
21
States / cities
Los Angeles, California • Santa Ana, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 8, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

ALS and Airway Clearance (ALSAC) Therapy

NCT04947436
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Respiratory Muscle Weakness
Interventions
High Frequency Chest Wall Oscillation, Mechanical insufflation/exsufflation
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 8, 2026, 2:18 AM EDT
Not listed Not applicable Interventional

Concurrent Treatment for Patients With Cervical Radiculopathy

NCT03636009
View directory record Official record
Conditions
Spinal Nerve Root Disorder Nos
Interventions
concurrent traction and neuromobilization technique, sequential traction and neuromobilization technique, active exercise program, manual therapy to cervical and thoracic spine
Other
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 8, 2026, 2:18 AM EDT